{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-004552","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.396000+00:00","generated_at":"2026-06-19T03:58:36.856600+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner","bullets":["Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.","Full year 2022 net loss $192.3M ($1.25/share) vs $178.3M in 2021.","Cash and marketable securities $307.5M at Dec 31, 2022, down from $464.7M a year ago.","2023 GAAP operating expense guidance $310-330M; non-GAAP $275-295M.","Discontinuing material investments in sickle cell program; seeking collaboration partner for Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-004552","json":"https://secwatch.observer/filing/0001628280-23-004552.json","markdown":"https://secwatch.observer/filing/0001628280-23-004552.md","text":"https://secwatch.observer/filing/0001628280-23-004552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/0001628280-23-004552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/sgmo-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:58:36.856600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57c54cab1a388c47ad989473bd6006301bbc9bd7","claim":"SANGAMO THERAPEUTICS, INC reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 22, 2023, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/0001628280-23-004552-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}